Wrap Text
Form 8
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)
24 November 2022
FORM 8 (DD)
PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN
CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY
INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the ‘Code’)
1. KEY INFORMATION
(a) Full name of discloser: Petrus Jurgens Myburgh
(b) Owner or controller of interests and short N/A
positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is
insufficient. For a trust, the trustee(s), settlor and
beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose Mediclinic International plc
relevant securities this form relates:
Use a separate form for each offeror/offeree
(d) Status of person making the disclosure: Person acting in concert with the
e.g. offeror, offeree, person acting in concert with offeree (Mediclinic International
the offeror/offeree (specify name of offeror/offeree) plc)
(e) Date dealing undertaken: 21 November 2022
(f) In addition to the company in 1(c) above, is the N/A
discloser making disclosures in respect of any
other party to the offer?
If it is a cash offer or possible cash offer, state
“N/A”
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant
securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each
additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree
to which the disclosure relates following the dealing
Class of relevant security:
Interests Short positions
Number %(1) Number %
(2)
(1) Relevant securities owned 97 300 0.0132% Nil Nil
and/or controlled:
(2) Cash-settled derivatives: Nil Nil Nil Nil
(3) Stock-settled derivatives Nil Nil Nil Nil
(including options) and
agreements to
purchase/sell:
TOTAL: 97 300 0.0132% Nil Nil
(1)
Total number of ordinary shares of Mediclinic International plc is 737 243 810 as of 21 November 2022.
The percentages have been rounded to the four nearest decimal places.
(2)
Petrus Jurgens Myburgh owns 94 500 ordinary shares and a Person Closely Associated with Petrus
Jurgens Myburgh owns 2 800 ordinary shares.
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements
to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements
should be disclosed on a Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities (including directors’ and other employee
options)
Class of Mediclinic International plc ordinary shares of 10 pence each
relevant
security in
relation to
which
subscription
right exists:
Details, Short-Term Incentive Plan
including
nature of the Number of Date of grant Release date Exercise
rights ordinary price (per
concerned shares share)
and relevant 80 655 04/06/2021 05/06/2023 Nil
percentages 47 488 05/08/2022 05/08/2024 Nil
:
Long-Term Incentive Plan (subject to performance conditions)
Maximum Date of Vesting Lapse date Exercise
number of grant date price (per
ordinary share)
shares
awarded
216 411 14/12/2020 13/12/2025 14/12/2023 Nil
190 569 04/06/2021 03/06/2026 04/06/2024 Nil
148 319 05/08/2022 04/08/2027 04/08/2025 Nil
Long-Term Incentive Plan (not subject to performance conditions)(1)
Number of Date of grant Vesting date Exercise
ordinary price (per
shares share)
24 981 19/06/2019 18/06/2024 Nil
(1)
On 19 May 2022, the Remuneration Committee approved the vesting of the Long-
Term Incentive Plan Award granted to Petrus Jurgens Myburgh at 12.1% of
maximum based on the achievement against performance targets, equating to 24
981 shares. This award will be cash settled (as permitted under the remuneration
policy in place at the time and indicated in the Company's annual report for the
financial year ended 31 March 2019), as soon as practicable after vesting on 18 June
2024.
3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class
of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
(i) Party to an offer or person acting in concert (except for a principal trader in the
same group as a connected adviser)
Class of relevant Purchase/sale Number of Price per unit
security securities
N/A N/A N/A N/A
(ii) Principal trader where the sole reason for the connection is that the principal
trader is in the same group as a connected adviser
Class of Purchases/ Total number Highest price Lowest price
relevant sales of securities per unit per unit
security paid/received paid/received
N/A N/A N/A N/A N/A
(b) Cash-settled derivative transactions
Class of Product Nature of dealing Number of Price per
relevant description e.g. opening/closing a reference unit
security e.g. CFD long/short position, securities
increasing/reducing a
long/short position
N/A N/A N/A N/A N/A
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class Product Writing, Number Exercise Type Expiry Option
of description purchasing, of price e.g. date money
relevant e.g. call selling, securities per unit American, paid/
security option varying etc. to which European received
option etc. per unit
relates
N/A N/A N/A N/A N/A N/A N/A N/A
(ii) Exercise
Class of Product Exercising/ Number of Exercise price
relevant description exercised securities per unit
security e.g. call option against
N/A N/A N/A N/A N/A
(d) Other dealings (including subscribing for new securities)
Class of relevant Nature of dealing Details Price per unit (if
security e.g. subscription, applicable)
conversion
Mediclinic Vesting of award granted Vesting and cash N/A
International plc under the Company’s Short settlement of an
ordinary shares of Term Incentive Plan award over 13 383
10 pence each ordinary shares in
the Company
granted in respect
of the Company’s
financial year
ended 31 March
2020 under the
Company’s Short
Term Incentive
Plan
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding,
formal or informal, relating to relevant securities which may be an inducement to
deal or refrain from dealing entered into by the party to the offer or person acting in
concert making the disclosure and any other person:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state “none”
None.
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the party to the offer or person acting in concert making the disclosure and
any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to
which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None.
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
Date of disclosure: 23 November 2022
Contact name: Company Secretary, Link Company Matters
Limited
Caroline Emmet
Telephone number: +44 (0)333 300 1930
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s
dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
ABOUT MEDICLINIC INTERNATIONAL PLC
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its
markets.
At 30 September 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health
facilities, 21 day case clinics and 23 outpatient clinics. Hirslanden operated 17 hospitals and five day case
clinics in Switzerland with around 1 900 inpatient beds; Mediclinic Southern Africa operations included 50
hospitals (three of which in Namibia), five subacute hospitals, three mental health facilities and 14 day
case clinics (four of which operated by Intercare) across South Africa, and around 8 700 inpatient beds;
and Mediclinic Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with
around 1 000 inpatient beds in the UAE. In addition, under management contract Mediclinic Middle East
will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.
The Company’s primary listing is on the London Stock Exchange (‘LSE’) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.7% (2022: 29.9%) interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 24-11-2022 05:42:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
